The Safety and Effectiveness of Palonosetron Hydrochloride Capsule Was Used to CINV
ConditionNausea and Vomiting
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorXijing Hospital
About this trial
To observe and evaluate the safety and effectiveness of Palonosetron hydrochloride capsule in preventing acute nausea and vomiting caused by moderate emetic chemotherapy; The characteristics of the applicable population, clinical medication and clinical benefits of Palonosetron Hydrochloride Capsules were analyzed.
Eligibility criteria
Qualifiers
For patients with malignant tumors who can accept chemotherapy, the disease type is not limited. The specific chemotherapy scheme is the chemotherapy scheme with moderate risk of vomiting (for the risk level of vomiting, refer to the 2019 CSCO anti-tumor treatment related nausea and vomiting prevention and treatment guidelines);
18-75 years old, KPS score ≥ 70, and the expected survival time is more than 3 months;
Before treatment, ECG, blood routine test, liver and kidney functions and electrolytes were basically normal;
All patients signed the informed consent form
Disqualifiers
Patients with chemotherapy contraindications, patients allergic to 5-HT3RA, pregnant women and lactating women;
People with digestive tract obstruction; Patients with serious heart disease, liver and kidney disease and metabolic disorder; Patients suffering from epilepsy or using psychotropic and sedative drugs;
Used antiemetic drugs or chemicals within 24 hours.Those who have vomited before treatment may have brain metastasis, intracranial hypertension, gastrointestinal obstruction, psychological abnormalities, etc.Patients with factors causing nausea and vomiting.
Trial design
Treatments tested in this trial
- Palonosetron hydrochloride capsules
Treatment groups
1,060 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov